Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: A Bayesian mixed-treatment comparison analysis

Therapeutics and Clinical Risk Management

Volumn 11, Issue , 2015, Pages 1325-1335

  Migliore, Alberto ^a   Bizzi, Emanuele ^a   Egan, Colin Gerard ^b   Bernardi, Mauro ^c   Petrella, Lea ^d  

^a FATEBENEFRATELLI HOSPITAL   (Italy)

^b Primula Multimedia SRL   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Biologics; Meta analysis; Mixed treatment comparison; Monotherapy; Rheumatoid arthritis; Tocilizumab

Indexed keywords

ADALIMUMAB; BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; METHOTREXATE; PLACEBO; TOCILIZUMAB;

ACR20; ACR50; ACR70; ARTICLE; BAYES THEOREM; BAYESIAN MIXED TREATMENT COMPARISON MODEL; DRUG EFFICACY; HUMAN; META ANALYSIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS;

EID: 84940758330     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/TCRM.S89678     Document Type: Article

References (61)

1. Kvien TK. Epidemiology and burden of illness of rheumatoid arthritis. Pharmacoeconomics. 2004;22(2 Suppl 1):1–12.
2. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the preva­lence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15–25.
3. Smolen JS, Landewé R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73(3):492–509.
4. Salliot C, Van Der Heijde D. Long term safety of methotrexate mono­therapy in rheumatoid arthritis patients: a systematic literature research. Ann Rheum Dis. 2009;68(7):1100–1104.
5. de Thurah A, Norgaard M, Harder I, Stengaard-Pedersen K. Compli­ance with methotrexate treatment in patients with rheumatoid arthritis: influence of patients’ beliefs about the medicine: a prospective cohort study. Rheumatol Int. 2010;30(11):1441–1448.
6. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low – results from RABBIT, the German biologics register. Arthritis Res Ther. 2006;8:R66.
7. Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis. 2007;66(10):1339–1344.
8. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum. 2008;59(2):234–240.
9. Lee SJ, Chang H, Yazici Y, Greenberg JD, Kremer JM, Kavanaugh A. Utilization trends of tumor necrosis factor inhibitors among patients with rheumatoid arthritis in a United States observational cohort study. J Rheumatol. 2009;36(8):1611–1617.
10. Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in rheuma­toid arthritis and autoimmune diseases: data from the French registries. Rheumatology. 2011;50(1):222–229.
11. Soliman MM, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL. Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011;70(4):583–589.
12. Pappas DA, Reed GW, Saunders K, et al. Characteristics associated with biologic monotherapy use in biologic-naive patients with rheumatoid arthritis in a US registry population. Rheumatol Ther. 2015;2:85–96.
13. Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis. 2008;66(2):77–85.
14. Cimzia® (Certolizumab pegol) [summary of product characteristics]. Available from: http://www.ema.europa.eu/docs/es_ES/document_library/EPAR_-_Product_Information/human/001037/WC500069763.pdf. Accessed November 8, 2013.
15. Enbrel® (Etanercept) [summary of product characteristics]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000262/WC500027361.pdf. Accessed November 8, 2013.
16. Humira® (Adalimumab) [summary of product characteristics]. Avail­able from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000481/WC500050870.pdf. Accessed November 8, 2013.
17. Roactemra® (Tocilizumab) [summary of product characteristics]. Avail­able from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000955/WC500054890.pdf. Accessed November 8, 2013.
18. Remicade® (Infliximab) [summary of product characteristics]. Avail­able from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000240/WC500050888.pdf. Accessed November 8, 2013.
19. Simponi® (Golimumab) [summary of product characteristics]. Avail­able from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000992/WC500052368.pdf. Accessed November 8, 2013.
20. MabThera® (Rituximab) [summary of product characteristics]. Avail­able from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf. Accessed November 8, 2013.
21. Kineret® (Anakinra) [summary of product characteristics]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000363/WC500042310.pdf. Accessed November 8, 2013.
22. Orencia® (Abatacept) [summary of product characteristics]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000701/WC500048935.pdf. Accessed November 8, 2013.
23. Gabay C, Emery P, van Vollenhoven R, et al; ADACTA Study Investi­gators. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381(9877):1541–1550.
24. Nixon RM, Bansback N, Brennan A. Using mixed treatment compari­sons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. Stat Med. 2007;26(6):1237–1254.
25. Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. Pharmacotherapy. 2011;31(1):39–51.
26. Sutton AJ, Abrams KR. Bayesian methods in meta-analysis and evi­dence synthesis. Stat Methods Med Res. 2001;10(4):277–303.
27. Jonas DE, Wilkins TM, Bangdiwala S, et al. Findings of Bayesian Mixed Treatment Comparison Meta-Analyses: Comparison and Exploration Using Real-World Trial Data and Simulation [Internet]. Rockville, MD: Agency for Healthcare Research and Quality (US); 2013.
28. Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis. 2011;70(3):266–271.
29. Schmitz S, Adams R, Walsh CD, Barry M, FitzGerald O. A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approach. Ann Rheum Dis. 2012;71(2):225–230.
30. Aaltonen KJ, Virkki LM, Malmivaara A, Konttinen YT, Nordström DC, Blom M. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One. 2012;7(1):e30275.
31. Hochberg MC, Berry S, Broglio K, et al. Mixed treatment comparison of efficacy and tolerability of biologic agents in patients with rheumatoid arthritis. Curr Med Res Opin. 2013;29(10):1213–1222.
32. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. Semin Arthritis Rheum. 2010;39(6):425–441.
33. Turkstra E, Ng SK, Scuffham PA. A mixed treatment comparison of the short-term efficacy of biologic disease modifying anti-rheumatic drugs in established rheumatoid arthritis. Curr Med Res Opin. 2011;27(10):1885–1897.
34. Gallego-Galisteo M, Villa-Rubio A, Alegre-del Rey E, Márquez-Fernández E, Ramos-Báez JJ. Indirect comparison of biological treat­ments in refractory rheumatoid arthritis. J Clin Pharm Ther. 2012;37(3):301–307.
35. Felson DT, Anderson JJ, Boers M, et al. American College of Rheuma­tology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 1995;38(6):727–735.
36. Orme ME, Macgilchrist KS, Mitchell S, Spurden D, Bird A. Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatol­ogy criteria scores 20, 50, and 70. Biologics. 2012;6:429–464.
37. Lunn DJ, Best N, Thomas A, Wakefield J, Spiegelhalter D. Bayesian analysis of population PK/PD models: general concepts and software. J Pharmacokinet Pharmacodyn. 2002;29(3):271–307.
38. Spiegelhalter D, Thomas A, Best N, Lunn D. Win-BUGS User Manual: Version 1.4. Cambridge, MA: MRC Biostatistics Unit; 2003.
39. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation (Statistics in Practice). Chichester, England: John Wiley & Sons Ltd; 2004.
40. Caldwell D, Ades A, Higgins J. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Br Med J. 2005;331(7521):897–900.
41. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet. 2009;373(9665):746–758.
42. Welton NJ, Caldwell DM, Adamopoulos E, Vedhara K. Mixed treat­ment comparison meta-analysis of complex interventions: psycho­logical interventions in coronary heart disease. Am J Epidemiol. 2009;169(9):1158–1165.
43. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann Intern Med. 1999;130(6):478–486.
44. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000;343(22):1586–1593.
45. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis. 2004;63(5):508–516.
46. Klareskog L, van der Heijde D, de Jager JP, et al; TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet. 2004;363(9410):675–681.
47. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combina­tion therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. 2006;54(1):26–37.
48. Maini RN, Taylor PC, Szechinski J, et al; CHARISMA Study Group. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum. 2006;54(9):2817–2829.
49. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active con­trolled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66(9):1162–1167.
50. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab mono­therapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.
51. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19(1):12–19.
52. Nam JL, Ramiro S, Gaujoux-Viala C, et al. Efficacy of biologi­cal disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):516–528.
53. Diamantopoulos A, Benucci M, Capri S, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15(3):576–585.
54. Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ. Cost-ef­fectiveness of adalimumab, etanercept, and tocilizumab as first-line treat­ments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2012;15(2):340–351.
55. Jansen JP, Buckley F, Dejonckheere F, Ogale S. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs – a system­atic review and network meta-analysis. Health Qual Life Outcomes. 2014;12:102.
56. Tanaka T, Hishitani Y, Ogata A. Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics. 2014;8:141–153.
57. Burmester GR, Feist E, Kellner H, et al. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70:755–759.
58. Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview (review). Cochrane Database Syst Rev. 2011;(2):CD008794.
59. Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheu­matic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis. 2013;72(4):583–589.
60. Ramiro S, Gaujoux-Viala C, Nam JL, et al. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis. Ann Rheum Dis. 2014;73(3):529–535.
61. American College of Rheumatology Committee to Reevaluate Improve­ment Criteria. A proposed revision to the ACR20: the hybrid measure of American College of Rheumatology response. Arthritis Rheum. 2007;57(2):193–202.